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ABSTRACT
The Sox10 transcription factor is a central regulator
of vertebrate neural crest and nervous system de-
velopment. Its expression is likely controlled by
multiple enhancer elements, among them U3 (alter-
natively known as MCS4). Here we analyze U3
activity to obtain deeper insights into Sox10
function and expression in the neural crest and its
derivatives. U3 activity strongly depends on the
presence of Sox10 that regulates its own expression
as commonly observed for important developmental
regulators. Sox10 bound directly as monomer to at
least three sites in U3, whereas a fourth site
preferred dimers. Deletion of these sites efficiently
reduced U3 activity in transfected cells and trans-
genic mice. In stimulating the U3 enhancer, Sox10
synergized with many other transcription factors
present in neural crest and developing peripheral
nervous system including Pax3, FoxD3, AP2a,
Krox20 and Sox2. In case of FoxD3, synergism
involved Sox10-dependent recruitment to the U3
enhancer, while Sox10 and AP2a each had to bind
to the regulatory region. Our study points to the im-
portance of autoregulatory activity and synergistic
interactions for maintenance of Sox10 expression
and functional activity of Sox10 in the neural crest
regulatory network.
INTRODUCTION
Sox10 is one of the central transcriptional regulators of
neural crest development (1–4). Following its loss or
mutation many aspects of neural crest development are
disturbed, leading to defects in many of the neural
crest-derived cell types and structures of the vertebrate
body including melanocytes, peripheral glia, the sympa-
thetic and the enteric nervous system. Its essential role is
highly conserved among vertebrates as evident from loss-
and gain-of-function studies and the analyses of spon-
taneous mutations in a wide range of species such as
zebraﬁsh, Xenopus, chicken, mouse and man (5–14).
Considering the importance of Sox10 for neural crest de-
velopment and the numerous contributions of the neural
crest to the vertebrate body plan, it is essential to under-
stand how Sox10 functions and how it is regulated in the
neural crest.
Hallmarks of such central regulators are their ability to
functionally interact with many other co-expressed tran-
scription factors in a regulatory network and to reinforce
their own expression in a positive autoregulatory loop.
Additionally, central regulators of development are often
governed in their expression by the combined action of
multiple, evolutionarily conserved enhancers in the
vicinity of their genes (15,16). Analysis of these enhancers
is therefore not only crucial to understand the expression
pattern of these regulatory factors. It also provides an
opportunity to see these factors at work in the context
of their regulatory network. Enhancer studies may also
reveal insights into human disease as many disease-
causing or predisposing genetic alterations in the human
genome affect non-coding regions.
Sox10 enhancers have been identiﬁed in recent years by
two complementary approaches. BAC transgenesis has
ﬁrst served to delineate the part of the genome in which
the enhancers are present, before bioinformatics was
employed to identify potential enhancers by way of their
evolutionary conservation (17–22). Consecutive functional
analyses of reporter transgenes have led to the identiﬁca-
tion of more than 10 different regions with enhancer
activity that are spread over a distance of at least 120kb
and localized both upstream as well as downstream of the
Sox10 gene. Alterations that affect these enhancers such
as spontaneously occurring deletions in the distal
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have been shown to disturb neural crest development in
mouse and chicken (17,23). Considering that heterozygous
mutations in the SOX10 coding region also lead to neural
crest defects (so-called neurocristopathies) in humans
including Waardenburg syndrome (in which melanocyte
development is disturbed) and Hirschsprung disease
(in which enteric nervous system development remains in-
complete) (10,24,25), it seems plausible that cases with
unclear molecular origin may result from such SOX10
enhancer mutations that may cause or predispose to
disease.
Two nomenclatures exist for the enhancers: one in
which the regulatory regions are designated as MCS
(Multiple-species Conserved Sequences) (18) and an alter-
native one in which the regions are referred to as U/D
(upstream/downstream) enhancers (20). Two of these en-
hancers are particularly active in the early neural crest
along most parts of the rostrocaudal axis including the
vagal and trunk neural crest. These are the U1/MCS7
and the U3/MCS4 regions that for the remainder will be
referred to as U1 and U3 regions (18,20). Both enhancers
continue to function during later times of embryonic de-
velopment in several derivatives of the neural crest
including the developing enteric nervous system and
Schwann cells as the glial cells along peripheral nerves
arguing that their impact on Sox10 expression is not re-
stricted to early phases of neural crest development. U3 is
0.4kb long and situated  28kb in front of the Sox10
gene; U1 is even further upstream.
Both U1 and U3 contain many potential binding sites
for transcription factors with occurrence in the early
neural crest and in neural crest derivatives. Without
mapping the exact binding sites we have shown in an
earlier study that the neural crest transcription factors
Pax3, AP2a, Lef1, Sox9 and Sox10 bind to U1 and
U3 in vitro (20). To get further insight into the regula-
tory network that is built from these factors, the
underlying functional interactions and the ability of
Sox10 to regulate its own expression, we here study the
mechanisms by which the U3 element regulates Sox10
expression.
MATERIALS AND METHODS
Transgenic animals
Sox10
+/lacZ and Sox10
+/rtTA mice in which Sox10 coding
sequences were replaced on one allele by lacZ marker or
reverse tetracycline-controlled transactivator (rtTA) se-
quences, and mice carrying the lacZ transgene under
control of the hsp68 minimal promoter and the mouse
U3 enhancer (U3-lacZ) have been described before
(7,20,26).
U3m2-lacZ resembled the previously described U3-lacZ
transgene but carried a mutation in site 2 that prevented
Sox10 binding (Figure 3A). In U3null-lacZ, inactivating
mutations were simultaneously introduced into sites 2, 5,
7 and 9. After separation from the vector backbone and
puriﬁcation, the U3-lacZ, U3m2-lacZ and U3null-lacZ
transgenes were each separately microinjected as
NotI/KpnI fragments into the male pronucleus of
fertilized FVB oocytes. Transgenic mice were generated
from injected oocytes according to standard techniques.
Founder mice and transgenic offspring were identiﬁed
and genotyped by PCR analysis of DNA prepared from
tail biopsies using the U3-speciﬁc forward primer 50-GAG
CCCTGCTCATAAACAAG-30 and the lacZ-speciﬁc
reverse primer 50-AGTAGCTGTCAGCGTCTGGT-30
(20). Determination of copy numbers in transgenic mice
was performed by quantitative PCR with lacZ-speciﬁc
primers followed by normalization to Sox10
+/lacZ mice.
Tissue preparation, histological staining,
immunohistochemistry and documentation
Embryos from 9.5 days post-coitum (dpc) to 11.5 dpc
underwent ﬁxation in 1% paraformaldehyde and were
stained for b-galactosidase activity by incubation in 1%
X-gal for several hours at 37 C either immediately as
whole mounts or after being frozen at  80 C and pro-
cessed to 20-mm transverse cryosections.
Alternatively, ﬁxation was in 4% paraformaldehyde
followed by cryoprotection in sucrose and storage at
 80 C in tissue freezing medium (Leica, Bensheim,
Germany). For immunohistochemistry, 10-mm cryotome
sections from the forelimb level of genotyped,
age-matched mouse embryos were incubated with
anti-b-galactosidase goat antiserum (1:500 dilution,
Biotrend), anti-Brn3.0 rabbit antiserum (1:300 dilution,
gift of Dr E. Turner, UCSD, San Diego, CA, USA) and
anti-Sox10 guinea pig antiserum (1:2,000 dilution) (27) as
primary antibodies. Secondary antibodies conjugated to
Cy2 and Cy3 immunoﬂuorescent dyes (Dianova) were
used for detection.
Hematoxylin–eosin staining was performed on trans-
verse sections of parafﬁn-embedded material. Samples
were analyzed and documented either with a Leica
DMR microscope equipped with a Leica DFC 420C
CCD camera (Wetzlar, Germany) or with a Leica
MZFLIII stereomicroscope equipped with an Axiocam
(Zeiss, Oberkochem, Germany).
Plasmids
Expression plasmids were derived from pCMV5 or
pCAGGS-IRES-nGFP, and thus carried coding se-
quences under control of the cytomegalovirus immediate
early promoter or the chicken b-actin promoter. The eu-
karyotic pCMV5 expression plasmids for AP2a, Pax3,
FoxD3, Lef1, b-catenin, Slug, Krox20, Sox2, Sox9 and
Sox10, and pCAGGS-Sox10-IRES-nGFP have been
described previously (12,20,28). As reporter gene con-
struct the U3-luc plasmid was used in wildtype or
mutagenized form. It contained the luciferase reporter
gene under control of the 0.4-kb U3 region (20)
upstream of the b-globin minimal promoter. SoxE and
AP2a binding sites within U3 were mutated using the
QuickChange XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA, USA).
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Fertilized chicken eggs were obtained from Lohmann
(Cuxhaven, Germany) and incubated in a humidiﬁed in-
cubator at 37.8 C. Embryos were staged according to
Hamburger and Hamilton (29) and at stage 10–11
injected into the lumen of the neural tube with
pCAGGS-IRES-nGFP-based expression plasmids at a
concentration of 2mg/ml. Electrodes were placed at either
side of the neural tube, and electroporation was carried
out using a BTX ECM830 electroporator delivering ﬁve
50-ms pulses of 30V. Then electrodes were reversed and
electroporation repeated to transfect both sides of the
neural tube. Transfected embryos were allowed to
develop for 24h before electroporated regions of the
neural tube were identiﬁed by GFP expression, dissected
and processed to RNA. RNA was reverse transcribed and
the resulting cDNA used for quantitative PCR (30). For
detection of chicken Sox10 the species-speciﬁc primers
50-CTCGCCGGGACCATCCATGGCA-30 and 50-AGG
CAGCCCCGCCAGCCTCCCC-30 were used at an an-
nealing temperature of 57 C.
Cell culture, transient transfection, extract preparation
and electrophoretic mobility shift assays
HEK 293 cells were maintained in Dulbecco’s modiﬁed
Eagle’s medium (DMEM) containing 10% fetal calf
serum (FCS) and transfected by the polyethylenimine
(PEI) technique using 10mg of empty pCMV5 plasmid,
pCMV5-Sox10 MIC (coding for amino acids 1–189 of
Sox10) or pCMV5-Sox10 per 100-mm plate. Forty-eight
hours post-transfection, cells were harvested for extract
preparation (31) and electrophoretic mobility shift assays
(EMSA) were performed with these extracts as described
(32) using
32P-labeled double-stranded oligonucleotides
containing putative SoxE binding sites (for sequences,
see Figure 3A). In some cases, antibodies against Sox10
and AP2a (12) were added during incubation.
Luciferase assay
N2a cells were maintained in DMEM containing 10%
FCS and transfected with SuperFect Transfection
Reagent (Qiagen, Hilden, Germany) on 24-well tissue
culture plates using varying amounts (2–500ng, usually
100ng) of pCMV5-based expression vectors and 500ng
of luciferase reporter plasmid. Cells were harvested 48h
post-transfection. Luciferase activity was determined in
the presence of luciferin substrate by detection of
chemiluminescence.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assays were performed
as described (33) on dissected, trypsinized 11.5-dpc-old
mouse embryos. Proteins were crosslinked to DNA in
1% formaldehyde. After addition of glycine, chromatin
was prepared and sheared to an avarage fragment length
of 300–600bp using a Sonoplus HD2070 homogenizer
(Bandelin, Berlin, Germany). Immunoprecipitations were
performed overnight at 4 C using guinea pig polyclonal
a-Sox10 antibodies as well as control pre-immune serum
and protein A sepharose beads. DNA was puriﬁed from
input and precipitated chromatin after crosslink reversal
and subjected to PCR. The following primer pairs were
used for detection in 33 cycles of standard PCR using an
annealing temperature of 57 C: 50-GGAGCCCTGCTCA
TAAACAA-30 and 50-CCATTGTCTCCGAAGGGTTA-
30 for mouse U3 and 50-GACGAAGGAGAAGCCTTG
TC-30 and 50-ACTGCGACTCTGCTGTCTCT-30 for
mouse U4 (20).
GST pulldowns and western blotting
For pulldown experiments, glutathione-S-transferase
(GST) or GST fusion proteins with parts of Sox10 were
produced in Escherichia coli strain BL21 DE3 pLysS and
bound in the presence of DNaseI to glutathione sepharose
4B beads (28). An aliquot of the washed and equilibrated
beads, now carrying GST or GST fusion protein, was
incubated with extracts from 293 cells transfected with
AP2a or FoxD3 expression plasmids in interaction
buffer (20mM HEPES pH 7.9, 10mM KCl, 5mM
MgCl2, 0.5mM EDTA, 5% glycerol, 1mM dithiothreitol,
0.05% Triton-X 100 and 100mM NaCl). After centrifu-
gation and washing, bead-bound proteins from the 293
extracts were separated by SDS–PAGE, transferred to a
nitrocellulose membrane and detected by antibodies
directed against the speciﬁc tag attached to AP2a
(T7-tag) and FoxD3 (HA-tag) (12) as described (28).
RESULTS
The U3 enhancer is activated by many transcription
factors with occurrence in neural crest and peripheral glia
Previous EMSA had shown that the U3 enhancer binds
in vitro several transcription factors that inﬂuence neural
crest development (20). To address the functional rele-
vance of this in vitro binding activity, we analyzed
whether these transcription factors also inﬂuence the
ability of U3 to activate expression of a luciferase
reporter gene under control of a minimal promoter in
transiently transfected cultured cells. We used N2a neuro-
blastoma cells for our analyses as these tumor cells are
derived from and still exhibit some similarities to neural
crest cells. Among the neural crest transcription factors
tested, Pax3, FoxD3, the combination of Lef1 and
b-catenin, and AP2a each activated U3-dependent
luciferase expression (Figure 1A–D). Activation rates
were sensitive to the exact amount of transcription
factor present in the cells and maximal rates were
between 6- and 8-fold. Co-transfection with the neural
crest transcription factor Slug did not lead to reporter
gene activation at any concentration tested (Figure 1E).
High reporter gene induction rates were also obtained in
the presence Sox10 or its close relatives Sox9 and Sox8
with maximal induction rates above 15-fold for Sox10
and Sox9, and above 10-fold for Sox8 (Figure 1F–H).
These results argue that many, but not all transcription
factors with inﬂuence on neural crest development have
the ability to activate U3 in tissue culture.
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derivatives during later phases of development, we also
included Sox2 and Krox20 in our study as two transcrip-
tion factors with phase-speciﬁc occurrence and relevance
in developing Schwann cells (34–37). Again, we found
both transcription factors to strongly activate U3 and cor-
respondingly increase luciferase expression in transiently
transfected N2a cells with maximal induction rates of
13- and 18-fold, respectively (Figure 1I and J). We
conclude that U3 can mediate the effects of many tran-
scription factors that are expressed during the right time
and in the right cells to be bona ﬁde regulators of Sox10
expression.
The U3 enhancer may participate in Sox10 autoregulation
Intriguingly, U3 is strongly activated by four different Sox
proteins. Sox9-dependent activation may be important for
Sox10 induction in the early emigrating neural crest (11),
while Sox2 activity may be important for Sox10 expres-
sion in immature Schwann cells (35). Sox10 as a key regu-
lator of neural crest development may use the U3 enhancer
to maintain its expression in an autoregulatory loop.
To see whether Sox10 has the capability to regulate the
expression of its own gene, we electroporated neural tubes
of chicken embryos with a rat Sox10 cDNA construct,
and analyzed the impact of ectopic expression of rat
Sox10 on the endogenous expression of chicken Sox10
by RT–PCR using chicken-speciﬁc primers. These
studies revealed a 2.7-fold average induction of en-
dogenous Sox10 expression 24h after electroporation
(Figure 2A). This strongly argues for an autoregulatory
ability of Sox10.
To ﬁnd evidence for a role of the U3 enhancer in this
autoregulation, we next compared expression of a U3-lacZ
transgene (20) in wildtype and Sox10-deﬁcient (i.e.
Sox10
rtTA/rtTA) embryos at 11.5 dpc (26). This comparison
proved that transgene expression in the neural crest-
derived dorsal root ganglia (DRG) is strongly reduced
in vivo in the absence of Sox10 (Figure 2B and C).
Hematoxylin–eosin staining showed that DRG at rostral
trunk levels are already hypomorphic at mid-
embryogenesis in a Sox10-deﬁcient background
(Figure 2D). Reduced transgene expression at rostral
levels may therefore be secondary to neural crest cell
loss. At more caudal levels, however, DRG have a
normal size and still contain the normal number of
neural crest cells (Figure 2D) as previously reported in
the literature (7,38). The strong reduction of lacZ expres-
sion in caudal DRG of U3-lacZ, Sox10
rtTA/rtTA embryos
(Figure 2C) can thus not be attributed to neural crest cell
Figure 1. U3 activity in transiently transfected neuroblastoma cells is modulated by many transcription factors with occurrence in the neural crest
and its derivatives. Transient transfections were performed in N2a cells with a luciferase reporter under control of the Sox10 U3 enhancer and the
b-globin minimal promoter (U3-luc, 500ng per well). Empty pCMV expression plasmids ( ) or expression plasmids for various transcription factors
were co-transfected as indicated below the bars. Expression plasmids coded for Pax3 (A, increasing amounts of 10, 25, 100, 200 or 500ng per well as
indicated by the triangle), FoxD3 (B, 100ng per well), Lef1 and b-catenin (C, 200 and 25ng per well, respectively), AP2a (D, 10, 25, 100, 200 or
500ng per well), Slug (E, 10, 25, 100, 200 or 500ng per well), Sox10 (F, 10, 25, 100, 200 or 500ng per well), Sox9 (G, 25ng per well), Sox8 (H, 500ng
per well), Sox2 (I, 10, 25, 100, 200 or 500ng per well) and Krox20 (J, 10, 25, 100, 200 or 500ng per well). Luciferase activities in extracts from
transfected cells were determined in three experiments each performed in duplicates. The luciferase activity obtained for U3-luc in the absence of
ectopic transcription factor was arbitrarily set to 1. Fold inductions in the presence of transcription factors were calculated and are presented as
mean±SEM. Determined inductions were statistically signiﬁcant according to Student’s t-test (P 0.001).
Nucleic AcidsResearch, 2012,Vol. 40,No. 1 91loss and indicates that Sox10 is indeed required to
maintain U3 activity at least in these structures. Direct
determination of U3-lacZ transgene activity in extracts
from caudal regions of wildtype and Sox10-deﬁcient
embryos conﬁrmed this conclusion (Figure 2E).
In all likelihood, autoregulation requires Sox10 to
directly bind to the U3 enhancer. To address this
question, we prepared crosslinked chromatin from
11.5-dpc-old embryos and performed chromatin
immunoprecipitations. Indeed, we were able to enrich
the U3 enhancer in chromatin precipitated by antibodies
directed against Sox10 (Figure 2F). Such enrichment was
not observed for U3 with control IgG antibodies, nor was
it seen for another evolutionarily conserved control
fragment from the Sox10 genomic locus (U4) after pre-
cipitation with Sox10-speciﬁc antibodies. We therefore
conclude that Sox10 inﬂuences U3 activity by directly
binding to the enhancer.
The Sox10 U3 enhancer contains multiple conserved
binding sites for Sox proteins
Standard chromatin immunoprecipitations do not have
the resolution to exactly map the binding sites for Sox10
within this 0.4-kb long enhancer. Bioinformatic analysis
and visual inspection revealed the presence of nine sites
within U3 that conformed in sequence to the Sox consen-
sus 50-(A/T)(A/T)CAA(A/T)G-30 and were conserved
among various mammalian species as well as between
mouse and chicken (Figure 3A). As binding site predic-
tions are not very reliable for Sox proteins (39), we tested
in EMSA whether these sites really bind Sox10 with high
afﬁnity. Like all SoxE proteins, Sox10 exhibits both a
dimeric as well as a monomeric mode of binding (31,40).
This is evident from the formation of complexes with
distinct mobilities on the prototypic monomeric binding
site B and the dimeric binding site C/C0 (Figure 3B) (41).
Of the nine potential sites present within U3, sites 2, 5, 7
and 9 exhibited the strongest binding, whereas sites 1, 3, 4,
6 and 8 exhibited only weak or no Sox10 binding at all
(Figure 3B). As the CAA core of site 6 was approximately
1 helix turn away from the CAA core of site 5, it seemed
possible that sites 5 and 6 function as a dimeric site.
Figure 2. Sox10 autoregulates its own expression at least partly
through the U3 enhancer. (A) pCAGGS-IRES-nGFP-based expression
plasmids were injected into HH10-11 chicken neural tubes before
double-sided electroporation. Electroporated, GFP-expressing regions
of the neural tube were dissected 24h later and processed to RNA as
outlined on the left. Expression levels of endogenous Sox10 were
determined by RT–PCR in chicken neural tubes electroporated with
empty expression plasmid ( ; arbitrarily set to 1) and compared to
those in neural tubes electroporated with rat Sox10 expression
plasmids (+). Shown is the mean±SEM from ﬁve values. (B, C)
LacZ activity was detected colorimetrically using X-gal substrate in
whole embryos at 11.5 dpc. Embryos carried the lacZ reporter as a
U3-lacZ transgene on wildtype (Sox10+, B) or Sox10-deﬁcient
Sox10
rtTA/rtTA (Sox10 , C) background. Whole-mount stainings were
documented from the side. DRG in rostral (rDRG) and caudal regions
(cDRG) are marked. Size bar corresponds to 2mm and is valid for
(B, C). (D) Hematoxylin–eosin staining of transverse sections of
wildtype (Sox10+) and Sox10-deﬁcient (Sox10 ) 10.5 dpc-old
embryos at rostral and caudal levels corresponding to the positions
marked by arrowheads in (C). The DRG are next to the spinal cord
(sc) as indicated in the diagram and encircled by dotted lines. Size bar
corresponds to 25mm. (E) Chemiluminescent determination of U3-lacZ
transgene activity in extracts from caudal regions of wildtype (Sox10+)
and Sox10-deﬁcient Sox10
rtTA/rtTA (Sox10 ) 10.5-dpc-old embryos.
(F) Immunoprecipitation was performed on formaldehyde crosslinked
chromatin obtained from 11.5-dpc-old wildtype embryos in the absence
(buffer) and presence of antibodies (PI, pre-immune serum; a-Sox10,
anti-Sox10 antibodies). PCR was applied on the immunoprecipitate to
detect U3 and the evolutionarily conserved U4 region located between
U3 and the transcriptional start of Sox10. These regions of the Sox10
locus were also ampliﬁed from 1/10 of the material used for
immunoprecipitation (input). H2O, water control.
92 Nucleic AcidsResearch, 2012,Vol. 40,No. 1Figure 3. The U3 enhancer contains multiple binding sites for Sox10. (A) Comparative alignment of U3 sequences from mouse, rat, human, dog,
opossum and chicken. Putative Sox binding sites 1–9 are marked in gray. Putative other binding sites are boxed with solid lines for AP2a and FoxD3
(f) and with stippled lines for Pax3 (p) and Krox20 (k). Conﬁrmed binding sites are additionally highlighted by capital letters. The lines above the
sites indicate the regions used as oligonucleotides for EMSA. (B) EMSA with radiolabeled, double-stranded oligonucleotides encompassing sites 1–9
as indicated below the gels. Oligonucleotides were incubated in the absence ( ), or presence (C, Sox10) of protein extracts before gel electrophoresis
as indicated above the lanes. Extracts were from mock-transfected 293 cells (C) or 293 cells expressing Sox10 MIC (Sox10). Oligonucleotides with
sites B and C/C0 from the Mpz promoter (41) served as control for high-afﬁnity monomeric and dimeric Sox10 binding. All oligonucleotides were
size-matched. m, bound monomer; d, bound dimer; ns, non-speciﬁc complex.
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oligonucleotide that contained both sites. When such a site
5/6 oligonucleotide was used, we indeed obtained a
complex with lower mobility (Figure 3B). The fact that
this complex was dominant over the fast migrating
monomer-speciﬁc complex in the presence of sufﬁcient re-
maining free probe is indicative of cooperative binding of
two Sox10 molecules, i.e. dimer binding. The U3 enhancer
thus contains the three preferred monomeric sites 2, 7 and
9 and the dimeric site 5/6.
To test the functional signiﬁcance of these binding sites,
we introduced mutations into each of these sites that
completely destroyed the CAA core. EMSA veriﬁed that
the mutated sites were no longer able to bind Sox10 (data
not shown). Mutant U3 sequences were then tested in
reporter gene assays for their ability to respond to Sox
proteins. All U3 enhancer sequences with a single
mutant site were less inducible by Sox10 than the
wildtype in transiently transfected N2a cells (Figure 4A).
Mutation of site 2 furthermore exhibited the most severe
effect with Sox10-dependent transactivation being reduced
to <20% of the wildtype U3 enhancer (Figure 4A). In
contrast, mutations of site 5, site 7 or site 9 reduced
Sox10-dependent activation rates only to 45% of the
Figure 4. U3 responsiveness to Sox proteins in transiently transfected neuroblastoma cells diminishes after mutation of Sox binding sites. Transient
transfections were performed in N2a cells with the U3-luc reporter in wildtype or various mutant versions (500ng per well). Mutant U3 either carried
mutations in one of the three major monomeric binding sites 2, 7 and 9, in site 5 or site 6 as halves of the dimeric site or in successively increasing
numbers of binding sites as indicated below the bars. All U3-luc variants were co-transfected with empty expression plasmids or expression plasmids
for Sox10 (500ng per well, A), Sox9 (25ng per well, B), Sox8 (500ng per well, C) and Sox2 (100ng per well, D). Luciferase activities in extracts from
transfected cells were determined in three experiments each performed in duplicates. The fold induction obtained with a particular Sox protein for
wildtype U3-luc was arbitrarily set to 100% and transactivation rates obtained for the U3-luc mutants are presented relative to this value as
mean±SEM. A one-way analysis of variance (ANOVA) with Tukey’s multiple comparison post-test conﬁrmed the statistical signiﬁcance of the
detected differences in Sox10-dependent activation rates between wildtype and mutant U3-luc reporters (P 0.001).
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on its own, a site 6 mutation caused a similar decrease in
Sox10-dependent activation rate as the site 5 mutation
(Figure 4A). This supports the notion that sites 5 and
6 function as a dimer site. Even after mutation of all
three monomeric and the dimeric site, Sox10 retained
 10% of its transactivation capacity. This may be due
to the presence of additional low afﬁnity sites in U3.
Analogous transfections with Sox9 or Sox8 yielded
similar results with site 2 mutations again having the
strongest effect (Figure 4B and C). In case of Sox2, the
effect of a site 2 mutation was less pronounced, and
mutation of site 5 or site 6 had no effect on
Sox2-dependent U3 activity (Figure 4D). Even after
mutation of all monomeric and the dimeric site,
Sox2-dependent transactivation of U3 was only reduced
by half. This may be taken as evidence that Sox2 has dif-
ferent binding site preferences than Sox9 and Sox10 and
may thus function through some of the sites that bound
Sox10 only in limited amounts.
The Sox protein binding sites within the U3 enhancer are
functional in vivo
To conﬁrm the functional relevance of the mapped Sox
binding sites for activity of the U3 enhancer during em-
bryonic development, we generated transgenic mice with
mutant versions of the U3-lacZ reporter (Figure 5A). As
Sox binding site 2 had the strongest effect on
Sox10-dependent enhancer activity in N2a cells, we
generated the U3m2-lacZ transgene in which solely site 2
was mutated. U3null-lacZ, in contrast, contained
inactivating mutations in all three monomeric and the
single dimeric Sox binding site. For each of the transgenes,
at least three different founders were obtained that
transmitted the transgene to their offspring (Figure 5B).
Transgene numbers varied from 3 to 22 copies for
wildtype U3-lacZ, from 1 to 6 copies for U3m2-lacZ and
from 1 to 49 copies for U3null-lacZ. Copy numbers had no
inﬂuence on expression patterns and only little inﬂuence
on expression levels that were well comparable among
progenies from different founders for each transgenic
construct.
Whereas the wildtype U3-lacZ reporter exhibited strong
expression in the branchial arches, facial mesenchyme and
throughout the forming peripheral nervous system
including cranial ganglia and DRG at 9.5 dpc
(Figure 5D) and thus resembled the Sox10 expression
pattern (Figure 5C), there was only very low expression
of the U3m2-lacZ reporter in branchial arches and periph-
eral nervous system when analyzed at the level of the
Figure 5. Early embryonic activity of the U3 enhancer depends on
intact Sox binding sites. (A) The wildtype U3-lacZ transgene and its
two mutant versions U3m2-lacZ and U3null-lacZ are shown. Each con-
struct contains U3 sequences, the hsp68 minimal promoter (hsp), the
lacZ marker gene (lacZ) and a SV40 polyA signal (pA). (B) Summary
of copy numbers and expression levels in the different lines obtained for
each transgenic construct. s, strong expression; l, low expression;
r, residual expression. (C–J) LacZ activity was detected colorimetrically
using X-gal substrate on whole embryos at 9.5 dpc (C–F) and at 11.5
dpc (G–J). Embryos carried a lacZ reporter integrated into the Sox10
genomic region (Sox10
+/lacZ) or one of the transgenes depicted in A.
Whole-mount stainings were documented from the side and are repre-
sentative of strong (D, H), low (E, I) and residual (F, J) staining
intensities observed for each transgenic construct. BA, branchial
arches; CG, cranial ganglia; FM, facial mesenchyme; OV, otic vesicle.
Size bars in (C) and (G) correspond to 1mm and are valid for (C–F)
and (G–J), respectively.
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showed even less residual expression at 9.5 dpc
(Figure 5F).
When whole-mount analysis was performed 2 days
later, very similar results were obtained. At this level of
resolution the expression pattern of the wildtype U3-lacZ
reporter closely resembled Sox10 expression at 11.5 dpc.
The main difference was the lack of expression of the
U3-lacZ transgene in the otic vesicle despite it being a
major expression site of Sox10 (compare Figure 5G with
Figure 5H). The U3m2-lacZ reporter, in contrast, ex-
hibited only low level expression throughout most of the
typical Sox10 expression sites. Some residual staining was
detectable in the DRG (Figure 5I). At 11.5 dpc, the
U3null-lacZ reporter showed virtually no expression
(Figure 5J). These ﬁndings conﬁrm that the Sox binding
sites are absolutely essential for U3 activity during early
and mid-embryonic development. The monomeric site
2 obviously has a signiﬁcant contribution to that function.
The results from whole-mount stainings were comple-
mented by stainings of embryo sections at 11.5 dpc to
increase resolution. These stainings conﬁrmed previous
ﬁndings on the expression of the U3 enhancer (20) with
strong lacZ reporter expression along peripheral nerves, in
sympathetic ganglia and the enteric nervous system
(compare Figure 6E, I and M with Figure 6F, J and N).
Although DRG strongly express Sox10, U3-lacZ expres-
sion was relatively low in this structure of the peripheral
nervous system, consistent with loss of U3 activity around
this time (compare Figure 6A with Figure 6B). Similarly,
melanoblasts of the skin expressed Sox10, but not the
U3-lacZ transgene (compare Figure 6Q with Figure 6R).
Neither U3m2-lacZ nor U3null-lacZ showed signiﬁcant
expression in any of the sites where wildtype U3-lacZ
occurs at 11.5 dpc (Figure 6G, H, K, L, O and P).
Melanocytes in the skin were as much negative for
U3m2-lacZ and U3null-lacZ expression as they were
negative for U3-lacZ expression (Figure 6R–T). The
already weak expression of the U3-lacZ transgene in
DRG was even further reduced for the U3m2-lacZ trans-
gene and again completely missing for the U3null-lacZ
transgene (Figure 6B–D).
Immunohistochemistry with antibodies directed against
Sox10 as a marker for glial cells within the DRG and
against Brn-3.0 as a marker for sensory neurons addition-
ally indicated that the few lacZ-expressing cells that
remained in DRG of U3m2-lacZ transgenic mice
(compare Figure 6U with Figure 6V) were almost exclu-
sively Brn-3.0-positive sensory neurons and not
Sox10-positive glia (Figure 6X and Z). LacZ-expressing
cells in DRG of Sox10
+/lacZ mice, in contrast, were
instead glia (Figure 6W and Y). We thus have Figure 6. Loss of Sox binding sites decreases proper U3 activity and
causes weak ectopic activity. (A–T) LacZ reporter activity was detected
colorimetrically using X-gal substrate in transverse sections of the trunk
of 11.5-dpc-old Sox10
+/lacZ embryos (A, E, I, M, Q) and age-matched
embryos carrying the wildtype U3-lacZ transgene (B, F, J, N, R), the
U3m2-lacZ transgene (C, G, K, O, S) or the U3null-lacZ transgene
(D, H, L, P, T). Speciﬁc parts of the peripheral nervous system
including DRG (A–D), peripheral nerves (PN) (E–H), sympathetic
ganglia (SG) (I–L) and enteric nervous system (ENS) (M–P) are
shown as well as a skin region containing melanoblasts (Q–T). (U–Z)
Co-immunohistochemistry was performed on transverse sections of the
trunk of 11.5-dpc-old Sox10
+/lacZ embryos (U, W, Y) and age-matched
embryos carrying the U3m2-lacZ transgene (V, X, Z) using antibodies
directed against b-galactosidase (LacZ, in red) in combination with
antibodies directed against Sox10 as a marker for glia (W, X) and
Brn-3.0 as a marker for sensory neurons (Y, Z) (both in green). Only
DRG are shown. Size bars: 200mmi n( A) (valid for A–P), 50mmi n( Q)
(valid for Q–T), 25mmi n( U) (valid for U, V) and 5mmi n( Z) (valid for
W–Z).
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mutant enhancer is in a cell type in which Sox10 is
normally not expressed at this time. Loss of site 2 thus
not only strongly decreases the proper activity of the U3
enhancer but also causes weak ectopic activity.
Sox10 cooperates with other neural crest transcription
factors in regulating U3 activity
Considering that U3 responds not only to Sox10 and
closely related Sox proteins, but additionally to many
other transcription factors, we wanted to ﬁnd out
whether U3 responds to combinations of these factors
and thereby integrates their effects. When we transfected
the U3-luc reporter with combinations of Sox10 and a
second activating transcription factor, we achieved a
more than additive effect on U3 activity in many of
these combinations. Pax3 and Sox10 led to a 40-fold
increase in U3-luc activity on average (Figure 7A), while
Sox10 and FoxD3 activated U3 activity 30-fold
(Figure 7B). Even more impressive was the joint effect
of Sox10 and Krox20, Sox10 and Sox2 or Sox10 and
Figure 7. U3 is synergistically activated by transcription factor combinations in transiently transfected neuroblastoma cells. Transient transfections
were performed in N2a cells with wildtype (wt) or mutant U3-luc reporter plasmids (500ng per well) as indicated below the lanes. Mutant versions
include U3 enhancers with mutated AP2a site (A1m), mutated Sox10 binding site 9 (m9) and mutated Sox10 binding sites 2, 5, 7 and 9 (m2,5,7,9).
Sox10 expression plasmid (500ng in A–C) was co-transfected with the reporter, alone ( ) or in combination with plasmids for Pax3, Sox2, Krox20
(all 500ng, A), FoxD3 (100ng, B) and AP2a (10ng, C) as indicated below the bars. Luciferase activities in extracts from transfected cells were
determined in three experiments each performed in duplicates. The luciferase activity obtained for luciferase reporter in the absence of ectopic
transcription factor was arbitrarily set to 1. Fold inductions in the presence of transcription factors were calculated and are presented as
mean±SEM. Determined inductions were statistically signiﬁcant according to Student’s t-test (P 0.001). The white stippled line in the bars
from transfections with transcription factor combinations represent the sum of activation rates obtained with both transcription factors alone.
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and 90-fold, respectively (Figure 7A and C). The U3
enhancer can thus be synergistically activated by many
transcription factors in combination with Sox10. At the
same time, we failed to detect synergistic activations of the
U3 enhancer when Pax3, FoxD3, AP2a and Krox20 were
paired in different combinations in the absence of Sox10
(data not shown). While this may be due to technical
reasons, it is tempting to speculate that the presence of a
Sox protein is essential for synergistic activation.
To determine the mechanistic basis for synergistic acti-
vation, we concentrated on the interplay of FoxD3 and
AP2a with Sox10. Binding site prediction and visual in-
spection revealed only two potential binding sites each for
FoxD3 and AP2a (Figure 3A). However, when we per-
formed EMSA with FoxD3 and either one of its potential
binding sites, we failed to obtain a complex (data not
shown). This is in agreement with our previous inability
to detect FoxD3 binding to larger fragments of the U3
enhancer (20). At the same time, we made an interesting
observation in luciferase assays with a reporter under the
control of a U3 enhancer with mutations in all of the four
prominent Sox10 binding sites. Not only were the
Sox10-dependent activation and the synergistic effect
with FoxD3 abolished, but additionally, the FoxD3-
dependent activation was also strongly reduced
(Figure 7B). We conclude from these ﬁndings that
FoxD3 may be recruited to the U3 enhancer by Sox10
without having to bind to the enhancer on its own. This
is somewhat at odds with the observation that FoxD3
activates the U3 enhancer in N2a cells up to 7-fold in
the absence of co-transfected Sox10 (Figure 1B).
However, it has to be taken into account that N2a cells
express low levels of endogenous Sox9 that may be
capable of recruiting FoxD3 to U3 in the absence of
Sox10 (data not shown).
Analogous EMSA with AP2a revealed that the putative
site A1 shows binding, but not A2 (Figure 8A).
Interestingly, A1 is located at one of the U3 ends in
close vicinity of Sox10 binding site 9 and exhibits only
limited evolutionary conservation (Figure 3A). Mutation
of the core of A1 abolished binding of AP2a (Figure 8A).
When analyzed for its effects on U3 enhancer activity in
luciferase assays, this mutation turned U3 unresponsive to
AP2a while it did not interfere with Sox10-dependent ac-
tivation (Figure 7C and data not shown). Additionally,
the mutant U3 enhancer could no longer be synergistically
activated by the combination of Sox10 and AP2a
(Figure 7C).
As already mentioned, the identiﬁed AP2a site is near
Sox10 binding site 9. Therefore, we also tested how Sox10
and AP2a behave on a U3 enhancer with mutant site 9. As
already reported, Sox10-dependent enhancer activity was
reduced, but not abolished, while there was no effect on
AP2a-dependent activation. Intriguingly, the rate of syn-
ergistic activation was also dramatically decreased
(Figure 7C). When the site 9 mutant of the U3 enhancer
was replaced by a version with all prominent Sox10
binding sites mutated, the effect was even more
pronounced with Sox10-dependent and synergistic
Figure 8. Mechanistic aspects of the synergistic activation of the U3 enhancer by Sox10, AP2a and FoxD3. (A) EMSA with radiolabeled
double-stranded oligonucleotides encompassing the AP2a binding sites A1 and A2 (see Figure 3A). For A1, a wildtype and mutant version
(A1m) were used, in which the CCAGGC core was altered to a CCAATT. Oligonucleotides were incubated in the absence ( ) or presence (C,
AP2) of protein extracts before gel electrophoresis as indicated above the lanes. Extracts were from mock-transfected 293 cells (C) or 293 cells
expressing AP2a (AP2). (B) EMSA with a radiolabeled probe encompassing the AP2a binding site A1 and the Sox10 binding site 9 (A1+site9). The
probe was incubated before gel electrophoresis without extract (-) or with extracts from mock-transfected 293 cells (C) or 293 cells expressing AP2a
(AP2), full-length Sox10 (Sox10) or a combination of both (AP2+Sox10). Antibodies against AP2a (AbA) or Sox10 (AbS) were added to some
reactions as indicated above the lanes. ns, non-speciﬁc complex; AP2, AP2a-containing complex; Sox10, Sox10-speciﬁc complex; tc, ternary complex;
asterisk, supershifted complex. (C) Schematic diagram of the conserved regions of Sox10 which were fused to GST and used for pulldown experi-
ments. (D) GST pulldown experiments were performed on extracts from 293 cells expressing AP2a (AP2) or FoxD3. In addition to GST, proteins
were used for pulldown that contained the dimerization (Dim), HMG, K2 or transactivation (TA) domain of Sox10. Detection of the precipitated
AP2a and FoxD3 proteins was in western blots by antibodies directed against the T7-tag present in AP2a and the HA-tag present in FoxD3.
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indicate that both AP2a and Sox10 have to bind to the
enhancer to achieve synergistic activation.
Considering the importance of the identiﬁed AP2a site
and the adjacent Sox10 binding site 9 for the synergism,
we next performed EMSA with a probe that spanned both
sites (Figure 8B). This larger probe already interacted with
proteins from control extracts (ns in Figure 8B). Extracts
containing either full-length AP2a or full-length Sox10
yielded additional complexes of speciﬁc mobility whose
identity was conﬁrmed by the application of speciﬁc
antibodies. Both the AP2a-speciﬁc antibody and the
Sox10-speciﬁc antibody supershifted the corresponding
binary complexes. When both AP2a and Sox10 were
present in the extract, a novel band appeared with a
mobility lower than each of the two binary complexes.
Incubation with either AP2a- or Sox10-speciﬁc antibodies
identiﬁed this novel band as a ternary complex between
both proteins and the probe.
As there may be protein–protein contacts between
Sox10 and AP2a in the ternary complex, we performed
GST pulldown assays in which full-length AP2a was
tested for its ability to bind to various regions of Sox10
that were produced as GST fusions and immobilized on
sepharose beads (Figure 8C). These pulldown experiments
revealed that AP2a interacts both with a fragment con-
taining the HMG domain and the adjacent dimerization
region of Sox10 and with a fragment containing the
conserved K2 domain (Figure 8D). No interaction was
observed between AP2a and the transactivation domain
of Sox10 (Figure 8D). We conclude that AP2a interacts
with multiple regions of Sox10 that may in turn facilitate
its binding to the U3 enhancer so that cooperative binding
may constitute at least part of the mechanism by which
synergism is achieved in this case. Finally, it remains to be
mentioned that FoxD3 also interacted in GST pulldown
experiments with the fragment containing HMG domain
and dimerization region (Figure 8D) further conﬁrming
that Sox10 likely has the capability to recruit FoxD3 to
the U3 enhancer.
DISCUSSION
We have shown in this study that the U3 enhancer
strongly responds to Sox10 both in cultured cells and
in vivo. As we have also provided evidence for
autoregulation of Sox10 in vivo, it is reasonable to
assume that the U3 enhancer is involved in mediating
this Sox10 autoregulation during development of the
neural crest and its derivatives. Such autoregulation con-
stitutes a convenient regulatory mechanism for a central
transcriptional regulator that is expressed in a particular
cell type for extended times or continuously after speciﬁ-
cation, and whose expression needs to be maintained.
Sox10 is such a regulator as its expression begins in the
emerging neural crest at the time when these cells start to
emigrate and continues in several neural crest-derived cell
types for quite some time after speciﬁcation (7–9, 42–44).
In peripheral glia such as Schwann cells along nerves and
enteric glia in the gastrointestinal tract, Sox10 remains
expressed even into the fully matured and terminally
differentiated state (30,42).
In addition to Sox10, several other neural crest and glial
transcription factors activate the U3 enhancer. Our studies
indicate that these transcription factors function synergis-
tically with Sox10. While U3 enhancer activity in trans-
fected N2a cells can be induced by single factors, it is very
likely that U3 activity in vivo requires their concerted
action. This would explain why mutation of Sox binding
sites is sufﬁcient to inactivate U3 almost completely in
transgenic mice. The central role of Sox10 for U3
activity is also supported by our observation that syner-
gistic effects were readily detected in transcription factor
combinations with Sox10, but not in combinations
without Sox10 or a related Sox protein.
Synergistic action is an important functional principle
for Sox proteins and several Sox proteins have been
reported to switch cooperating transcription factors
during the course of development (39,45,46). While
Pax3, AP2a and FoxD3 may help Sox10 to maintain U3
activity in neural crest cells, these factors are no longer
present in peripheral glia. Instead, immature peripheral
glia express Sox2 and glia maturing to myelinating
Schwann cells induce Krox20. Now these transcription
factors may help Sox10 to maintain activity of the U3
enhancer.
In the course of this study, we have analyzed two syn-
ergistic interactions in closer detail. Intriguingly, the
underlying mechanisms seem to vary, although physical
interactions between Sox10 and other transcription
factors seem to be generally important. That many such
interactions exist has been shown before (28). Krox20 is,
for instance, a known interaction partner of Sox10 (28).
Considering that we detected a physical interaction
between Sox10 and FoxD3, but failed to see direct
binding of FoxD3 to speciﬁc sites in U3 enhancer, the
synergism between Sox10 and FoxD3 appears to be
based on the Sox10-dependent recruitment of FoxD3 to
the enhancer. In contrast, synergism between AP2a and
Sox10 required both proteins to bind to their own sites in
U3. Existing physical interactions between AP2a and
Sox10 may facilitate this binding. Interestingly, AP2a
contacts two separate Sox10 regions. It is actually
the ﬁrst protein shown to interact with the K2 domain,
a region that contributes to the function of Sox10,
but whose mode of action is still poorly understood
(12,47).
In the absence of transcription factors that are able to
synergize with Sox10, U3 activity likely subsides. This will
for instance be the case in sensory neurons of the periph-
eral nervous system in which Sox10 and U3 activity are
not maintained despite the origin of these cells from
Sox10-positive neural crest cells (7). Our current study
and the resulting model thus gives important insights
into the mechanisms by which maintenance of Sox10 ex-
pression may be achieved, but also provides important
clues how the positive autoregulatory loop may be
broken and Sox10 expression be extinguished.
It needs to be emphasized that autoregulation cannot
solely be responsible for Sox10 expression. This is for
instance evident from the fact that some residual
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lacZ reporter remains detectable in
Sox10-deﬁcient mice, as long as the normally
Sox10-expressing cells survive in its absence (7). There
are two likely explanations. Some of the other enhancers
(i.e. U1 and U5) whose activities overlap with U3 may not
depend as strictly on autoregulation as U3.
Additionally, it has to be taken into consideration that
the Sox10 binding sites in U3 and the other enhancers will
also be recognized by other Sox proteins, in particular by
the closely related Sox8 and Sox9 that have very similar, if
not identical binding characteristics and form the SoxE
subgroup with Sox10 (31,32,40,48). This assumption is
conﬁrmed by our reporter studies in transiently trans-
fected cells. Particularly Sox9 may be important in vivo,
as it precedes Sox10 in the neural crest and has been
shown to induce Sox10 expression (11,49). Sox9 may
thus induce Sox10 in the emerging neural crest via U3.
At later times Sox10 appears to be the dominant SoxE
protein in such neural crest derivatives as peripheral glia
(1) so that Sox8 and Sox9 are unlikely to contribute as
much to maintenance of Sox10 expression as they do to its
induction.
Our studies in transgenic mice did not only show the
importance of the identiﬁed Sox protein binding sites in
general, but also pointed to an essential role of binding
site 2 in agreement with tissue culture studies. Site 2 binds
a single molecule of Sox10. This is noteworthy because
previous studies have placed greater emphasis on the
role of dimeric sites. Dimeric sites can only be properly
used by SoxE and a few other Sox proteins and are there-
fore more speciﬁc than the standard monomeric sites. It
has even been postulated that the occurrence of dimeric
sites can be used to predict regulatory regions with neural
crest activity bioinformatically (18). While our study does
not question the importance of dimeric sites, of which one
is indeed present in U3, it clearly shows that monomeric
sites are likewise essential to guarantee Sox10-dependent
activity in neural crest and glial cells. Future studies may
also address the question whether all four of the identiﬁed
Sox10 binding sites are needed in vivo for activity or
whether some sites (such as site 2) dominate functionally.
The presence of multiple binding sites and the ability of
Sox proteins to change the topology of bound DNA as
architectural factors (39,50) at least permits the attractive
hypothesis that multiple binding is required to alter the
three-dimensional conformation of U3 from an inactive
into an active state.
Finally, it would be interesting to screen patients with
neurocristopathies of unexplained cause for sequence
polymorphisms in the Sox10 binding sites of U3 as
identiﬁed in this study. Such sequence polymorphisms
may turn out to be inactivating mutations that
may lead to developmental defects in neural crest or per-
ipheral glia.
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